Abbvie Inc
NYSE: ABBV
$190.17
+$6.27 (+3.4%)
Closing Price on February 3, 2025
ABBV Articles
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Published:
Last Updated:
The Franchise Picks list makes sense for solid growth investors looking for total return. Many of the stocks pay good dividends and have upside price potential.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Published:
Last Updated:
Buying high-yielding blue chips for 2016 makes good sense. The Federal Reserve interest rate increases over the next two years are expected to remain very small and very measured.
Published:
Last Updated:
You may want to avoid these stocks over the next few months.
Published:
Last Updated:
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Published:
Last Updated:
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
Published:
Last Updated:
Buying stocks such as these, with solid growth potential and paying dividends higher than the 10-year Treasury debt, makes good sense now.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, Apple, Autodesk, JD.com, CyberArk, Dean Foods and Walt Disney.
Published:
Last Updated:
AbbVie reported better-than-expected third-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
AbbVie is expected to report its third-quarter financial results before the markets open on Friday.
Published:
Gilead Sciences is set to report its third-quarter financial results after the markets close on Thursday.
Published:
The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Published:
Each week we cover the new value calls from the analysts at Jefferies, and more and more, some of the calls may look surprising.
Published:
These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the course of the past week.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.